Phase 1 N=80 CC-42344 Safety Study in Healthy Participants
Influenza A
Primary: Part 1 SAD: Number of Participants With Treatment-Emergent Adverse Events (TEAE) — 3; 3; 6; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=54 A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants
Multiple Sclerosis · Colitis, Ulcerative
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 3; 2; 6 Participants
Phase 1 N=36 A Safety Study of AZD4041 in Healthy Participants
Opioid Use Disorder (OUD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 8; 6; 6; 9 Participants
Phase 1 N=56 Dose-finding Pharmacokinetic Study in Healthy Males
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Phase 1 N=49 MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects
Healthy
Primary: Safety and Tolerability of N91115 — 9; 6; 6; 6 participants
Phase 1 N=9 Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
Healthy
Primary: Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) Post-Baseline — 0; 0; 0; 0 participants
Phase 1 N=40 TAK-935 Multiple Rising Dose Study in Healthy Participants
Epilepsy
Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) — 40.0; 0; 16.7; 83.3 percentage of participants
Phase 1 N=24 A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
Phase 1 N=44 Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects
Safety · Healthy Subjects
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 8; 4; 2; 5 Participants
Phase 1 N=78 Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers
Healthy
Primary: Percentage of Subjects With Drug Related Adverse Events — 16.7; 16.7; 33.3; 0.0 percentage of participants
Phase 1 N=47 AZD8848 Single Ascending Dose Study
Healthy
Primary: Adverse Events — 6; 2; 1; 0 participants
Phase 1 N=24 A Safety Study of PTI-125 in Healthy Volunteers
Alzheimer Disease, Early Onset · Alzheimer Disease
Primary: Maximum Plasma Concentration (Cmax) — 315; NA; 550; NA ng/mL
Phase 1 N=41 Safety and Tolerability Study of N6022 in Healthy Subjects
Healthy
Primary: Safety and Tolerability of a Single Ascending Doses of Intravenous N6022 in Healthy Volunteers — 1; 4; 1; 0 Adverse Events
Phase 1 N=60 Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
Chikungunya Virus
Primary: Part A: Number of Participants With Any Solicited Adverse Events (AEs) (Local and Systemic Reactogenicity Events) — 11; 10; 11; 10 Participants
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 1 N=40 A First-in-Human Study of LY3009385 in Healthy Participants
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Drug-related Adverse Events (AEs) or Any Serious AEs — 1; 1; 1; 2 participants
Phase 1 N=21 Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
Campylobacter Jejuni Infection
Primary: Count of Participants With Adverse Events — 0; 1; 3; 1 Participants
Phase 1 N=30 A Single Dose Study of LY3023703 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AE — 0; 0; 0; 0 Participants
Phase 1 N=70 STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in PART-1: SAD — 2; 1; 1; 0 Participants
Phase 1 N=40 A Safety Study of LY2886721 Single Doses in Healthy Subjects
Alzheimer's Disease
Primary: Number of Participants With Clinically Significant Effects (Adverse Events) — 0; 0; 0; 0 Participants
Phase 1 N=80 First in Man Trial of BI 113608
Healthy
Primary: Clinically Relevant Abnormalities for Clinical Laboratory Evaluation, Vital Signs, Lung Function, Carbon Monoxide Diffusing Capacity of the Lung, ECG, Physical…
Phase 1 N=76 Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants
Healthy Volunteers
Primary: Adverse Events — 0; 2; 3; 3 Participants
Phase 1 N=48 A Study of LY3079514 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Phase 1 N=70 Study of NST-6179 in Healthy Subjects
Short Bowel Syndrome · Parenteral Nutrition Associated Liver Disease
Primary: Number of Participants With AEs and SAEs Following Administration of NST 6179 — 4; 2; 2; 2 Participants
Phase 1 N=63 A Study of LY2951742 in Healthy Volunteers
Migraines
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 participants
Phase 1 N=32 A Study of RGLS8429 in Healthy Volunteers
Healthy Volunteers
Primary: Incidence of Adverse Events (AEs) — 0; 0; 0; 0 participants
Phase 1 N=32 To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
SARS-CoV-2 Infection
Primary: Preliminary Safety and Tolerability of CT-P59 — 0; 2; 1; 0 Participants
Phase 1 N=32 First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects
Hepatitis B
Primary: Number of Participants With Any Non-serious Adverse Event (AE); Any Serious AE (SAE); Any AEs Leading to Discontinuation of Study Treatment (AELD) in Part 1 — 4; 3; 2; 3…
Phase 1 N=54 A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants
Healthy Volunteers
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 2; 1; 1; 1 Participants
Phase 1 N=60 Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169
Healthy Subjects
Primary: Number of Adverse Events — 9; 4; 5; 2 AEs